WCO-IOF 2016: Daily subcutaneous abaloparatide vs teriparatide & placebo for osteoporosis

Study Type:Randomized Trial

OE Level Evidence:N/A

Journal Level of Evidence:N/A

Effects of abaloparatide on vertebral, nonvertebral, major osteoporotic and clinical fracture incidence in postmenopausal women with osteoporosis: result of the phase 3 ACTIVE trial

Contributing Authors: BJ Riis C Christiansen P Miller F Cosman LA Fitzpatrick D Black E Lau CAF Zerbini G Williams MY Hu G Hattersley

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

CONFERENCE ACE REPORTS

This ACE Report is a summary of a conference presentation or abstract. The information provided has limited the ability to provide an accurate assessment of the risk of bias or the overall quality. Please interpret the results with caution as trials may be in progress and select results may have been presented.

Access conference website and list of abstracts.